Evaluating the Expression and Prognostic Value of Genes Encoding Microtubule-Associated Proteins in Lung Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Dec 11

PMID 36499051

Authors

Natsaranyatron Singharajkomron

Varalee Yodsurang

Suthasinee Seephan

Sakkarin Kungsukool

Supinda Petchjorm

Nara Maneeganjanasing

Warunyu Promboon

Wadsana Dangwilailuck

Varisa Pongrakhananon

Affiliations

Soon will be listed here.

Abstract

Microtubule-associated proteins (MAPs) play essential roles in cancer development. This study aimed to identify transcriptomic biomarkers among MAP genes for the diagnosis and prognosis of lung cancer by analyzing differential gene expressions and correlations with tumor progression. Gene expression data of patients with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) from the Cancer Genome Atlas (TCGA) database were used to identify differentially expressed MAP genes (DEMGs). Their prognostic value was evaluated by Kaplan-Meier and Cox regression analysis. Moreover, the relationships between alterations in lung cancer hallmark genes and the expression levels of DEMGs were investigated. The candidate biomarker genes were validated using three independent datasets from the Gene Expression Omnibus (GEO) database and by quantitative reverse transcription polymerase chain reaction (qRT-PCR) on clinical samples. A total of 88 DEMGs were identified from TCGA data. The 20 that showed the highest differential expression were subjected to association analysis with hallmark genes. Genetic alterations in and correlated with the expression of most of these DEMGs. Of these, six candidates- and -were significantly differentially expressed and correlated with the overall survival (OS) of the patients. The mRNA expression profiles of these candidates were consistently verified using three GEO datasets and qRT-PCR on patient lung tissues. The expression levels of and can serve as diagnostic biomarkers for LUAD and LUSC. Moreover, the first five can serve as prognostic biomarkers for LUAD, while can be a prognostic biomarker for LUSC. Our research describes the novel role and potential application of MAP-encoding genes in clinical practice.

Citing Articles

Targeting Kinesins for Therapeutic Exploitation of Chromosomal Instability in Lung Cancer.

Zhang C, Wu B, Thu K Cancers (Basel). 2025; 17(4).

PMID: 40002279 PMC: 11853690. DOI: 10.3390/cancers17040685.

Adunctin E from Induces Apoptosis in Lung Cancer via HSP90AA1 Modulation: A Network Pharmacology and In Vitro Study.

Iksen I, Singharajkomron N, Nguyen H, Hoang H, Ho D, Pongrakhananon V Int J Mol Sci. 2024; 25(21).

PMID: 39518920 PMC: 11546842. DOI: 10.3390/ijms252111368.

WZ-3146 acts as a novel small molecule inhibitor of KIF4A to inhibit glioma progression by inducing apoptosis.

Yan T, Jiang Q, Ni G, Ma H, Meng Y, Kang G Cancer Cell Int. 2024; 24(1):221.

PMID: 38937742 PMC: 11209999. DOI: 10.1186/s12935-024-03409-y.

MAP4 acts as an oncogene and prognostic marker and affects radioresistance by mediating epithelial-mesenchymal transition in lung adenocarcinoma.

Xia X, Ge Y, Ge F, Gu P, Liu Y, Li P J Cancer Res Clin Oncol. 2024; 150(2):88.

PMID: 38341398 PMC: 10858930. DOI: 10.1007/s00432-024-05614-8.

A Comprehensive Genetic Study of Microtubule-Associated Gene Clusters for Male Infertility in a Taiwanese Cohort.

Chan C, Yen T, Tseng H, Mai B, Ho P, Chou J Int J Mol Sci. 2023; 24(20).

PMID: 37895049 PMC: 10607339. DOI: 10.3390/ijms242015363.

References

Edgar R, Domrachev M, Lash A . Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2001; 30(1):207-10. PMC: 99122. DOI: 10.1093/nar/30.1.207. View

Planchard D, Popat S, Kerr K, Novello S, Smit E, Faivre-Finn C . Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv192-iv237. DOI: 10.1093/annonc/mdy275. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Yang Y, Gao L, Weng N, Li J, Liu J, Zhou Y . Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Among Kinesin Superfamily of Proteins in Pancreatic Ductal Adenocarcinoma. Front Oncol. 2021; 11:708900. PMC: 8454465. DOI: 10.3389/fonc.2021.708900. View

Xia X, He C, Wu A, Zhou J, Wu J . Microtubule-Associated Protein 4 Is a Prognostic Factor and Promotes Tumor Progression in Lung Adenocarcinoma. Dis Markers. 2018; 2018:8956072. PMC: 5878896. DOI: 10.1155/2018/8956072. View

Ji Z, Pan X, Shang Y, Ni D, Wu F . KIF18B as a regulator in microtubule movement accelerates tumor progression and triggers poor outcome in lung adenocarcinoma. Tissue Cell. 2019; 61:44-50. DOI: 10.1016/j.tice.2019.09.001. View

Kim E . Chemotherapy Resistance in Lung Cancer. Adv Exp Med Biol. 2015; 893:189-209. DOI: 10.1007/978-3-319-24223-1_10. View

Shah D, Joshi M, Patel B . Role of NIMA-related kinase 2 in lung cancer: Mechanisms and therapeutic prospects. Fundam Clin Pharmacol. 2022; 36(5):766-776. DOI: 10.1111/fcp.12777. View

Schiewek J, Schumacher U, Lange T, Joosse S, Wikman H, Pantel K . Clinical relevance of cytoskeleton associated proteins for ovarian cancer. J Cancer Res Clin Oncol. 2018; 144(11):2195-2205. DOI: 10.1007/s00432-018-2710-9. View

10.

Gao J, Sai N, Wang C, Sheng X, Shao Q, Zhou C . Overexpression of chromokinesin KIF4 inhibits proliferation of human gastric carcinoma cells both in vitro and in vivo. Tumour Biol. 2010; 32(1):53-61. DOI: 10.1007/s13277-010-0090-0. View

11.

Baquero M, Lostritto K, Gustavson M, Bassi K, Appia F, Camp R . Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Res. 2011; 13(5):R85. PMC: 3262195. DOI: 10.1186/bcr2937. View

12.

Suh J, Johnson A, Albacker L, Wang K, Chmielecki J, Frampton G . Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. Oncologist. 2016; 21(6):684-91. PMC: 4912374. DOI: 10.1634/theoncologist.2016-0030. View

13.

Vaishnavi A, Capelletti M, Le A, Kako S, Butaney M, Ercan D . Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013; 19(11):1469-1472. PMC: 3823836. DOI: 10.1038/nm.3352. View

14.

Hu P, Chen X, Sun J, Bie P, Zhang L . siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo. Biosci Rep. 2014; 35(1). PMC: 4293903. DOI: 10.1042/BSR20140124. View

15.

Chen C, Peng S, Li P, Ma L, Gan X . High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR. Mol Cell Biochem. 2020; 475(1-2):15-25. DOI: 10.1007/s11010-020-03854-z. View

16.

Zheng S, Shi L, Zhang Y, He T . Expression of SNCG, MAP2, SDF-1 and CXCR4 in gastric adenocarcinoma and their clinical significance. Int J Clin Exp Pathol. 2014; 7(10):6606-15. PMC: 4230097. View

17.

Hammerman P, Sos M, Ramos A, Xu C, Dutt A, Zhou W . Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2012; 1(1):78-89. PMC: 3274752. DOI: 10.1158/2159-8274.CD-11-0005. View

18.

Jiang X, Jiang Y, Luo S, Sekar K, Koh C, Deivasigamani A . Correlation of NUF2 Overexpression with Poorer Patient Survival in Multiple Cancers. Cancer Res Treat. 2021; 53(4):944-961. PMC: 8524009. DOI: 10.4143/crt.2020.466. View

19.

Cusan M, Wang L . NEK2, a promising target in TP53 mutant cancer. Blood Sci. 2022; 4(2):97-98. PMC: 9362867. DOI: 10.1097/BS9.0000000000000106. View

20.

Wattanathamsan O, Pongrakhananon V . Emerging role of microtubule-associated proteins on cancer metastasis. Front Pharmacol. 2022; 13:935493. PMC: 9515585. DOI: 10.3389/fphar.2022.935493. View